Trial: 201810055

A Phase Ia/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of BTRC4017A Administered Intravenously as a Single Agent and in Combination with Trastuzumab in Patients with Locally Advanced or Metastatic Her2-Expressing Cancers



Principal Investigator

Park, Haeseong

Disease Site

Breast; Esophagus; Stomach

Learn more about this study at: